Show simple item record

Preemption Under the Controlled Substances Act

dc.contributor.authorMikos, Robert A.
dc.date.accessioned2022-05-05T18:39:03Z
dc.date.available2022-05-05T18:39:03Z
dc.date.issued2013
dc.identifier.citation16 Journal of Health Care Law & Policy 5 (2013)en_US
dc.identifier.urihttp://hdl.handle.net/1803/17217
dc.descriptionarticle published in law journalen_US
dc.description.abstractStates are conducting increasingly bold experiments with their marijuana laws, but questions linger over their authority to deviate from the federal Controlled Substances Act. The CSA bans marijuana outright, and commentators have assumed that Congress sought to preempt all state laws that might somehow conflict with the CSA. Under the preemption rule now in vogue, state marijuana reforms are preempted if they either require someone to violate the CSA or, more controversially, if they pose an obstacle to Congress’s objective of eradicating marijuana. Seeking to avoid such conflicts, government officials have scuttled a number of important state marijuana reforms. This Article aims to clarify state authority in this realm and to highlight more generally the dangers of embracing broad preemption rules. In particular, it suggests that the amorphous language of obstacle preemption has been used to block three types of state marijuana reforms that Congress either could not or clearly did not want to preempt: (1) laws that merely legalize marijuana-related activities; (2) laws that restrict such activities through novel means, such as licensing requirements for marijuana vendors; and (3) laws that only incidentally promote violations of the CSA, such as laws prohibiting employment discrimination against marijuana users. To avoid these mistakes, the Article proposes that courts and lawmakers employ a narrower and simpler direct conflict rule. Under this rule, state law is preempted only if it requires someone to violate the CSA. The Article shows why this direct conflict rule more closely comports with Congress’s preemptive authority and its preemptive designs. It also suggests that the rule should provide some much-needed clarity on an issue that has befuddled commentators for years.en_US
dc.format.extent1 PDF (36 pages)en_US
dc.format.mimetypeapplication/pdf
dc.language.isoen_USen_US
dc.publisherJournal of Health Care Law & Policyen_US
dc.titlePreemption Under the Controlled Substances Acten_US
dc.typeArticleen_US
dc.identifier.ssrn-urihttp://ssrn.com/abstract=2258123


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record